BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1616 related articles for article (PubMed ID: 31607641)

  • 21. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results.
    Carrato A; Vieitez JM; Benavides M; Rodriguez-Garrote M; Castillo A; Ogalla GD; Bermejo LG; Ruiz de Mena I; Guillén-Ponce C; Aranda E;
    Eur J Cancer; 2020 Nov; 139():51-58. PubMed ID: 32977220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.
    Zhang H; Kellett C; Lambert P; Kim CA
    Clin Colorectal Cancer; 2018 Sep; 17(3):e451-e456. PubMed ID: 29631907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
    Portal A; Pernot S; Siauve N; Landi B; Lepère C; Colussi O; Rougier P; Zaanan A; Verrière B; Taieb J
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e23-6. PubMed ID: 24559766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
    Assaf E; Verlinde-Carvalho M; Delbaldo C; Grenier J; Sellam Z; Pouessel D; Bouaita L; Baumgaertner I; Sobhani I; Tayar C; Paul M; Culine S
    Oncology; 2011; 80(5-6):301-6. PubMed ID: 21778770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
    Lee K; Bang K; Yoo C; Hwang I; Jeong JH; Chang HM; Oh D; Song TJ; Park DH; Lee SS; Lee SK; Kim MH; Park JH; Kim KP; Ryoo BY
    Cancer Res Treat; 2020 Jan; 52(1):254-262. PubMed ID: 31291709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
    Kim S; Signorovitch JE; Yang H; Patterson-Lomba O; Xiang CQ; Ung B; Parisi M; Marshall JL
    Adv Ther; 2018 Oct; 35(10):1564-1577. PubMed ID: 30209750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I Study.
    Safran H; Charpentier KP; Perez K; Mantripragada K; Miner T; DiPetrillo T; Kuritzky B; Apor E; Bishop K; Luppe D; Mitchell K; Rosati K
    Am J Clin Oncol; 2016 Dec; 39(6):619-622. PubMed ID: 26523444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
    Abrams TA; Meyer G; Meyerhardt JA; Wolpin BM; Schrag D; Fuchs CS
    Oncologist; 2017 Aug; 22(8):925-933. PubMed ID: 28476943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy.
    Templeton S; Moser M; Wall C; Shaw J; Chalchal H; Luo Y; Zaidi A; Ahmed S
    J Gastrointest Cancer; 2021 Jun; 52(2):529-535. PubMed ID: 32440849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study.
    Kim JH; Lee SC; Oh SY; Song SY; Lee N; Nam EM; Lee S; Hwang IG; Lee HR; Lee KT; Bae SB; Kim HJ; Jang JS; Lim DH; Lee HW; Kang SY; Kang JH
    Cancer Commun (Lond); 2018 Jun; 38(1):32. PubMed ID: 29866170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population.
    Hatashima A; Arango MJ; Reardon J; Freeman T; Williams T; McLaughlin EM; Abushahin L
    Future Oncol; 2022 Jun; 18(20):2521-2532. PubMed ID: 35579260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
    Zaibet S; Hautefeuille V; Auclin E; Lièvre A; Tougeron D; Sarabi M; Gilabert M; Wasselin J; Edeline J; Artru P; Bechade D; Morin C; Ducoulombier A; Taieb J; Pernot S
    Br J Cancer; 2022 Jun; 126(10):1394-1400. PubMed ID: 35094032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
    BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
    Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
    Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
    Tahara J; Shimizu K; Otsuka N; Akao J; Takayama Y; Tokushige K
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):245-250. PubMed ID: 29846765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
    N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis.
    Sasaki T; Kanata R; Yamada I; Matsuyama M; Ozaka M; Sasahira N
    In Vivo; 2019; 33(1):271-276. PubMed ID: 30587635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
    Ellenrieder V; König A; Seufferlein T
    Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
    Trouilloud I; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Asnacios A; Manet-Lacombe S; Fein F; Dubreuil O; Landi B; Zaanan A; Bonnetain F; Taïeb J
    Eur J Cancer; 2014 Dec; 50(18):3116-24. PubMed ID: 25454414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
    Queck A; Elango S; Koch C; Walter D; Schmidt J; Trebicka J; Trojan J; Pession U; Finkelmeier F; Waidmann O
    Oncol Res Treat; 2022; 45(3):79-87. PubMed ID: 34875671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 81.